Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Positives From Trump Plan Include Potential 340B Changes, Value-Based Contracts

Executive Summary

Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.

Advertisement

Related Content

Pharma’s Blame-The-Middleman Strategy Pays Off – For Now
Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan
Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
No Deal: Omnibus Spending Bill Moves Without Part D Discount Relief
CMS Efforts On Value-Based Payments Should Focus On Removing Barriers, PhRMA Says
Medicare Lowers Payments For 340B Drugs: Promising Sign For Further Reform?
CAR-T Indication-Based Pricing May Be Evaluated In Medicare Demo
Drug Payment Experiments Coming To Medicare, Medicaid

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel